Halozyme Therapeutics
Quarterly Financials
| Values in thousands | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 |
|---|---|---|---|---|
Revenue | $298,008 | $290,084 | $231,353 | $195,879 |
Gross Profit | 255,953 | 240,658 | 173,984 | 149,787 |
EBITDA | 203,169 | 190,033 | 137,597 | 115,748 |
EBIT | 182,754 | 169,671 | 117,235 | 95,542 |
Net Income | 137,012 | 137,011 | 93,245 | 76,823 |
Net Change In Cash | 298,008 | 290,084 | 231,353 | 195,879 |
Free Cash Flow | 175,415 | 113,859 | 53,212 | 125,881 |
Cash | 115,850 | 154,318 | 187,864 | 164,627 |
Basic Shares | 128,980 | 130,134 | 129,222 | 128,887 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $1,015,324 | $829,253 | $660,116 | $443,310 |
Gross Profit | 855,907 | 636,892 | 520,812 | 361,897 |
EBITDA | 551,475 | 451,947 | 315,506 | 278,899 |
EBIT | 470,163 | 367,091 | 265,865 | 275,902 |
Net Income | 444,091 | 281,594 | 202,129 | 402,710 |
Net Change In Cash | 1,015,324 | 829,253 | 660,116 | 443,310 |
Cost of Revenue | 115,476 | -28,984 | ||
Free Cash Flow | 468,368 | 373,277 | 235,300 | 297,983 |
Cash | 115,850 | 118,370 | 234,195 | 118,719 |
Basic Shares | 129,424 | 134,197 | 140,608 | 146,796 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-12-31 | $1.26 |
2024-09-30 | $1.27 |
2024-06-30 | $0.91 |
2024-03-31 | $0.79 |
